Stock Liao information

— Basic knowledge of stocks|Introduction to basics of stocks|Stock learning|Basic knowledge of stocks

The "new crown market" is far from over, these 9 stocks are expected to continue to benefit?

Release Time:2022-06-16 Topic:Geely Stock Quotes Today Reading:91 Navigation:Stock Liao information > Finance > The "new crown market" is far from over, these 9 stocks are expected to continue to benefit? phone-reading

As we finally close this 2020 book, we will never forget what happened when the coronavirus pandemic turned our world upside down. In the meantime, we'll wonder what's going to happen next. It's not just about President Trump, but the chaotic response within the entire federal government. Sadly, the crisis has not been managed optimally due to a variety of factors, which provides a reason to buy these stocks this week.

Clearly, the biggest talking point remains the coronavirus and how to deal with the threat. The Trump administration has taken the necessary steps to help stem the trend. For example, when Covid-19 raged across the globe, the president banned travel from China and Europe.

But the president's own will be a troubling issue in the general election. He has consistently refused to wear a mask in public, sometimes appearing to mock those who wear them. And, as his supporters tend to imitate his boisterous ways, they have essentially contributed to a culture war over curtailing efforts to fight the pandemic. From a cynical point of view, this supports the case for buying healthcare-related stocks.

Unfortunately, we have seen some setbacks in this area recently, due to security concerns High-profile treatments and vaccines have been forced to suspend their advanced clinical trials. It's a reminder of how alarming this race for solutions is.

Additionally, Trump's own Covid-19 illness -- and his refusal to specify when he last tested negative -- did little to help people feel good about him. With coronavirus cases still lingering high, these stocks to buy could benefit from a catalyst driven by media coverage.

Merck (NYSE:MRK)

Target (NYSE:TGT)

Johnson & Johnson (NYSE:JNJ)

Archer Daniels Midland (NYSE:ADM)

Gilead Sciences (NASDAQ:GILD)

Wheaton Precious Metals (NYSE:WPM)

Axon Enterprise (NASDAQ:AAXN)

Blink Charging (NASDAQ:BLNK)

Sturm Ruger (NYSE:RGR)

To maximize utility, I have grouped these companies into three categories ( There are three stocks in each category): companies with a high probability of upside but limited upside, companies with a balance between upside potential and risk, and the last category is downright speculative trades.

In the end, I think it's fair to say that the president has become increasingly detached from the American people. So perhaps it's wise to at least consider the possibility of buying stocks that would perform better under a Joe Biden administration.

Merck Merck & Co (MRK)

Regeneron Pharmaceuticals (NASDAQ:REGN) had a nice run last week on coverage of the presidential election, and now It may be time to turn your attention to a tried-and-true pharma giant like Merck & Co. While MRK is generally one of the best long-term stocks to buy under any circumstances, its popularity has picked up due to the recent setback for the Covid-19 vaccine.

While MRK stock didn't become a high-profile vaccine investment, the company behind it eventually joined the fray, albeit after others. Merck's vaccine candidate has two characteristics that differentiate it from competitors' products. First, it's potent enough to be prescribed in just one dose. Second, the vaccine is taken orally.

This can be logistically heavybig impact because many vaccine candidates must be frozen. Likewise, a single-dose regimen can have a miraculous effect on patient availability and even a desire to take it. While you may not be afraid of injections, injections are not the most comforting advice for most people.

Finally, once the pandemic is over, MRK stock will start to rise along with its robust pipeline of cancer drugs. Plus, you can earn dividends while you wait for this terrible storm to end.

Target Target (TGT)

Perhaps the most underrated thing I can say is that 2020 has been an odd year. Specifically, what has made this year so unruly is the divergence between the two. On the one hand, millions of people face poverty due to the risk of not being able to pay their rent and, more recently, have been displaced by fires on the West Coast.

But on the other hand, those who were doing well before the pandemic are doing better today. From a dire perspective, the coronavirus may have given some people their best lives thanks to "perks" like working from home. Well, to settle this divide, there's probably no better retailer than Target.

With the holidays coming, TGT stock could benefit from pent-up demand, especially those "benefiting" from the coronavirus. Plus, Target has really strengthened the alternative delivery options that consumers prefer. So you might consider Target on your list of stocks to buy this week.

Equally important, big box retailers have other essentials that consumers demand. For example, the company has come a long way in expanding its grocery offerings over the years. In addition, Target sells other essential goods that could turn into valuable goods in the doomsday we are living in. So do yourself a favor and keep an eye on TGT stock.

Johnson & Johnson (JNJ)

As the race for a coronavirus vaccine unfolds among several "pure" biotech companies, Johnson & Johnson (JNJ) Johnson & Johnson) were not really involved in the discussions. Instead, many analysts believe in J&J stock because the company has many potential over-the-counter drugs that, so to speak, are in high demand for the average person.

At the time, Johnson & Johnson was offering what appeared to be a heavyweight product: a single-dose vaccine that didn't require refrigeration, improving the logistics of vaccine distribution. Most other vaccines require an injection in an early trial followed by a booster shot a few weeks later. That made Johnson & Johnson one of the better long-term stocks to consider until it also suffered a setback.

Similar to AstraZeneca (NASDAQ:AZN), a participant in Johnson & Johnson's Covid-19 vaccine trial has contracted an unexplained illness. While Johnson & Johnson's stock took a considerable hit the day after the news, it wasn't terrible.

However, I understand why some investors are hesitant. Still, the setback could cost investors a missed opportunity because the company still has a slew of other related drugs to help people cope with the crisis.

Archer Daniels Midland (ADM)

On the surface, food-related companies seem like the best stocks to buy during the pandemic. No matter who you are or how much money you have, you need to make ends meet. So this area seems obvious.

But things didn't go the way I expected. While companies like Kroger (NYSE:KR) and Costco (NASDAQ:COST) are doing well, individual food stocks leave a lot to be desired. So, if this recovery turns into a terrifying second wave, I'd pick Archer Daniels Midland and its stock.

As you know, Archer Daniels specializes in food processing and ingredients. They provide the solutions and ingredients all food manufacturers need to bring their products to market. For ADM stock, you can't count on any one name, but on the industry as a whole.

In addition, Archer Daniels is especially attractive to those interested in plant-based meat companies but don't want to take the risk of buying Beyond Meat (NASDAQ:BYND) stock. With ADM, you can be in this excitingindustry space, but can also potentially mitigate risks.

Gilead SciencesGilead Sciences (GILD)

Frankly, Gilead Sciences has been a disappointment in this pandemic. Early on, Gilead's remdesivir was touted as a promising treatment. However, GILD stock took a nosedive over the summer as competition for a vaccine intensified. Fundamentally, this seems odd since we knew from the start that vaccine development and distribution would take years.

In addition, competing therapies may also cast a shadow on the stock price. But when the most important people in the world need to seek treatment, remdesivir is again in the discussion. According to CNN, President Trump "is on a five-day course of antiviral drugs. Apparently, this is a PR boost for Gilead.

In addition, Trump's remdesivir package May help mitigate unsubstantiated support for hydroxychloroquine. According to the FDA's post-emergency authorization study for severely ill Covid-19 patients, "the drug neither speeds recovery nor prevents coronavirus infection in healthy people," The New York Times reported. or develop serious disease. ”

Wheaton Precious Metals (WPM)

It seems that no matter what the market conditions, gold is always risky. So you should be wondering whether WPM is the best Good gold stocks with reservations. That's not to say I don't believe in WPM stock - I do. Rather, it's an industry that has produced a lot of disappointment.

Nevertheless, it's as it is now and in the past Nothing happens any time. While we've suffered severe epidemics before - most notably the H1N1 pandemic in the late 2000s - we've never seen state and federal government mandated bans on going out. Unsurprisingly , which created a hard landing for the economy, making WPM stock attractive.

Mainly, those gloomy economic forecasts that pushed gold prices into five figures are now more plausible Believe it a bit. Frankly, the Fed doesn't have much monetary leverage other than being as accommodative as possible. In theory, that's a good thing for gold.

I also like WPM's Business model. As a precious metals streaming company, Wheaton has no direct risks associated with mining projects.

Axon Enterprise (AAXN)

In my view Come on, Wisconsin is a pretty peaceful place outside of football season and I'm sure its residents love it. However, this state, especially Kenosha, is making international headlines. This is where a white police officer shot a black father , Jacob Black, which left him paralyzed and required multiple surgeries.

In a startling video, Mr. Black was shown walking slowly towards his car. He turned his back to the police and was shot seven times . This is a sensitive matter, and I can't comment. What I can say, though, is that the visuals are absolutely horrible.

But I can't help but wonder, the things we didn't capture What? This is where police body cameras become critical, not only to protect good law enforcement officers - and let me be clear, most of them are good guys - but to hold bad guys accountable. So , I believe Axon Enterprise and its stock will have substantial long-term gains.

(Axon develops and sells conductive electronic weapons for personal defense)

No, I don't think it is A cynical play. Rather, it's a reality of our lives. Obviously, we can't have law enforcement shoot people in the back. But we can't have anarchy in the streets either.

Axon maybe Doesn't offer a satisfying middle ground, but it's one of the best solutions we have. As such, I'm bullish on AAXN stock.

Blink Charging (BLNK)

For years, the concept of range anxiety has clouded the optimistic outlook for electric vehicles. But more recently, improvements in EV battery technology have greatly eased that concern. However, for the platform to become truly mainstream, we also need to accelerate the development of charging infrastructure. That's part of the reason why Blink charge is a speculative stock to buy this week.

As you know, part of the marketing message of electric vehicles is their environmental friendliness. As far as I know, this is not too high on President Trump's agenda. but this isOne of the most important questions for the Biden team. Since the former vice president looks far less stupid than the current president, I think there's a good chance that Biden will accept the offer. In my opinion, the current price is not too low for BLNK stock.

In addition, many Americans live in apartments. According to data compiled by the National Multi-Family Housing Council, 17 percent of California residents are apartment dwellers. That's bad for EVs because it automatically weeds out potential buyers. But with charging facilities, EVs will benefit, which in turn will boost BLNK stock.

Sturm Ruger (RGR)

Of all the questions facing the present - President Trump has been given the easiest one to answer, namely condemn white supremacy.

But he gave a confusing answer, circling the question. Strong condemnation is not only the right answer, but also the most "profitable" answer for any other candidate. Supporting extremists will only get you a few votes at most, and make millions of others lose interest in you.

But this is the world we live in now, which is why I put Sturm Ruger on my list of stocks to buy this week. First, in a cynical sense, things have never looked better for RGR stock. Guns are a hot commodity amid social unrest and the general uncertainty of dealing with the pandemic.

However, with tensions now so high, we could see violence spill into the streets no matter who wins. Of course, I hope this is just my imagination. But judging by gun sales records, I don't think so. This suggests that RGR stock may recover soon.

The author of this article: Josh Enomoto, US stock research agency, aims to help Chinese investors understand the world, focus on reporting US technology stocks and Chinese stocks, and friends who are interested in US stocks quickly follow us

Article Url:

Label group:[stock] [problem vaccine] [Trump

Hot topic

Finance recommend

Finance Popular